NeurAxis Inc (NYSE:NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. The publication ...
Neuraxis Inc. has initiated a clinical study to evaluate the efficacy of its IB-Stim neuromodulation system in treating children with post-concussion syndrome (PCS). The aim is to see whether IB-Stim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback